Table 2.
Annual and cumulative chronic HCV treatment coverage among OAT patients in Norway between 2013 and 2017
| Source | 2013 | 2014 | 2015 | 2016 | 2017 | Total | |
| Chronic HCV treatment, n (overall) | NorPD | 146 | 167 | 243 | 322 | 597 | 1475 |
| DAAs, n | NorPD | 46 | 95 | 212 | 290 | 592 | 1235 |
| DAAs, % of HCV | 32 | 57 | 87 | 90 | 99 | 84 | |
| Study population, n, yearly including deaths | NorPD | 7709 | 7914 | 7958 | 7804 | 7709 | 10 371 |
| Deaths | NorPD | 165 | 151 | 138 | 114 | 124 | 692 |
| Study population, n, yearly, excluding deaths | NorPD | 7544 | 7763 | 7820 | 7690 | 7585 | 9679 |
| Prevalence chronic HCV, mean % | SERAF | 51 | 52 | 52 | 46 | 43 | |
| Prevalence chronic HCV, n | SERAF | 3847 | 4037 | 4066 | 3537 | 3262 | |
| Incidence chronic HCV among PWIDs, n | NIPH, Mejierick et al14 | 396 | 388 | 381 | 374 | 366 | |
| Incidence chronic HCV OAT from PWIDs, n | Expert opinion | 277 | 272 | 267 | 262 | 256 | |
| Treatment coverage chronic HCV, % | 3.5 | 3.9 | 5.6 | 8.5 | 17 | ||
| Cumulative frequency chronic HCV | 3.5 | 7.4 | 13 | 21.5 | 38.5 | ||
| 95% CI treatment coverage chronic HCV | 3.2 to 4.4 | 3.5 to 4.8 | 5.3 to 6.7 | 8.2 to 10.1 | 16.9 to 19.6 |
DAA, direct-acting antivirals; HCV, hepatitis C virus; NIPH, Norwegian Institute for Public Health; NorPD, Norwegian Prescription Database; OAT, opioid agonist therapy;PWID, people who inject drugs; SERAF, The Norwegian Centre for Addiction Research.